|
US3760984A
(en)
|
1971-09-29 |
1973-09-25 |
Alza Corp |
Osmotically powered agent dispensing device with filling means
|
|
US3952741A
(en)
|
1975-01-09 |
1976-04-27 |
Bend Research Inc. |
Controlled release delivery system by an osmotic bursting mechanism
|
|
CA2465328C
(en)
|
2001-11-01 |
2011-06-14 |
Michael Francis Gross |
Piperidines
|
|
US20060045822A1
(en)
|
2004-09-01 |
2006-03-02 |
Board Of Regents, The University Of Texas System |
Plasma polymerization for encapsulating particles
|
|
CN101056877B
(zh)
|
2004-09-14 |
2010-06-09 |
诺华疫苗和诊断公司 |
咪唑并喹啉化合物
|
|
AU2006213746A1
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
|
|
EP2700638A1
(en)
|
2006-05-31 |
2014-02-26 |
The Regents Of the University of California |
Purine analogs
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
TW200911803A
(en)
|
2007-07-16 |
2009-03-16 |
Organon Nv |
6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
|
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
|
TWI500617B
(zh)
|
2010-05-31 |
2015-09-21 |
Ono Pharmaceutical Co |
Purine ketone derivatives
|
|
PL2710005T3
(pl)
|
2011-05-17 |
2017-07-31 |
Principia Biopharma Inc. |
Inhibitory kinazy tyrozynowej
|
|
CN103502249A
(zh)
|
2011-05-17 |
2014-01-08 |
普林斯匹亚生物制药公司 |
作为酪氨酸激酶抑制剂的氮杂吲哚衍生物
|
|
MX354412B
(es)
|
2011-06-10 |
2018-03-05 |
Merck Patent Gmbh |
Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
|
|
US9199997B2
(en)
|
2011-11-29 |
2015-12-01 |
Ono Pharmaceutical Co., Ltd. |
Purinone derivative hydrochloride
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
WO2013191965A1
(en)
|
2012-06-18 |
2013-12-27 |
Principia Biopharma Inc. |
Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
|
|
SI2892900T1
(en)
|
2012-09-10 |
2018-01-31 |
Principia Biopharma Inc. |
Pyrazolopyrimidine compounds as kinase inhibitors
|
|
CN102942567B
(zh)
*
|
2012-11-09 |
2017-02-08 |
诸城市浩天药业有限公司 |
吡咯并喹啉醌的二钠盐结晶
|
|
EA201590855A1
(ru)
|
2012-11-15 |
2015-11-30 |
Фармасайкликс, Инк. |
Соединения пирролопиримидина как ингибиторы киназ
|
|
US20140142099A1
(en)
|
2012-11-20 |
2014-05-22 |
Principia Biopharma Inc. |
Purinone Derivatives as Tyrosine Kinase Inhibitors
|
|
KR102196882B1
(ko)
|
2012-12-20 |
2020-12-30 |
머크 샤프 앤드 돔 코포레이션 |
Hdm2 억제제로서의 치환된 이미다조피리딘
|
|
MX365640B
(es)
|
2012-12-21 |
2019-06-10 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
|
|
WO2015132799A2
(en)
|
2014-02-03 |
2015-09-11 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
|
ES2860648T5
(es)
*
|
2014-02-07 |
2024-11-27 |
Global Blood Therapeutics Inc |
Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
|
|
US10253023B2
(en)
|
2014-10-06 |
2019-04-09 |
Merck Patent Gmbh |
Heteroaryl compounds as BTK inhibitors and uses thereof
|
|
JP2016094368A
(ja)
*
|
2014-11-14 |
2016-05-26 |
大日本住友製薬株式会社 |
ベンズイミダゾール化合物の新規結晶、及びその製造方法
|
|
WO2016086358A1
(en)
|
2014-12-02 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Hydroxymethyl piperidine orexin receptor antagonists
|
|
UA124090C2
(uk)
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
CN105753863B
(zh)
*
|
2015-09-11 |
2018-07-31 |
东莞市真兴贝特医药技术有限公司 |
氧代二氢咪唑并吡啶类化合物及其应用
|
|
EP3414234B1
(en)
|
2015-10-14 |
2022-06-29 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
SI3377484T1
(sl)
|
2015-11-17 |
2024-02-29 |
Merck Patent Gmbh |
Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo
|
|
WO2019208805A1
(ja)
|
2018-04-27 |
2019-10-31 |
小野薬品工業株式会社 |
Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
|
|
BR112022014058A2
(pt)
*
|
2020-01-20 |
2022-09-13 |
Genzyme Corp |
Inibidores terapêuticos de tirosina cinase para esclerose múltipla recidivante (rms)
|
|
US12448363B2
(en)
|
2020-06-02 |
2025-10-21 |
Vidya Therapeutics, Inc. |
Kinase inhibitors
|
|
WO2022081512A1
(en)
|
2020-10-12 |
2022-04-21 |
Synubi Pharmaceuticals Llc |
Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors
|
|
AU2021398051A1
(en)
|
2020-12-10 |
2023-07-27 |
Principia Biopharma Inc. |
Crystal form of tolebrutinib, preparation method therefor and use thereof
|
|
US20240051955A1
(en)
|
2020-12-23 |
2024-02-15 |
Genzyme Corporation |
4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one derivatives and salts thereof
|
|
EP4328226A4
(en)
|
2021-04-23 |
2025-08-27 |
Hangzhou Solipharma Co Ltd |
CRYSTALLINE FORM, AMORPHOUS FORM OF TOLEBRUTINIB, PREPARATION PROCESS THEREOF AND USE THEREOF
|
|
CN117412749A
(zh)
|
2021-05-21 |
2024-01-16 |
杭州领业医药科技有限公司 |
Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途
|
|
WO2022257845A1
(zh)
|
2021-06-11 |
2022-12-15 |
苏州科睿思制药有限公司 |
Tolebrutinib的晶型及其制备方法和用途
|
|
JP7564347B2
(ja)
|
2021-09-03 |
2024-10-08 |
ノバルティス アーゲー |
多発性硬化症を治療するためのｌｏｕ０６４
|
|
US20250145618A1
(en)
|
2021-12-21 |
2025-05-08 |
Principia Biopharma Inc. |
Crystalline Forms of (R)-1-(1-Acryloylpiperidin-3-YL)-4-Amino-3-(4-Phenoxyphenyl)-1H-Imidazo[4,5-C]Pyridin-2(3H)-One and salts Thereof
|
|
US20260027100A1
(en)
|
2022-05-13 |
2026-01-29 |
Principia Biopharma Inc. |
Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad)
|
|
CA3259743A1
(en)
|
2022-06-22 |
2023-12-28 |
Principia Biopharma Inc. |
METHODS FOR MANUFACTURING MODIFIED BTK INHIBITORS
|
|
CA3260159A1
(en)
|
2022-06-30 |
2024-01-04 |
Principia Biopharma Inc. |
Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis
|